Full Professor(heuristic)

Advanced Breast Cancer Therapies · Pulmonary and Respiratory Medicine

Compare more Pulmonary and Respiratory Medicine professors.

h-index75
i10-index159
Publications691
Citations26,708

Grants

9 total · 2 active

NIH #R35CA305347

Overcoming Resistance to Targeted Therapy in Breast Cancer

Active
Amount
$1M–$2M
Period
2025-08-20 → 2032-07-31
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA296285

Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.

Active
Amount
$400K–$500K
Period
2025-08-01 → 2030-07-31
PIs
2

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #P50CA247749

Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer

Amount
$400K–$500K
Period
2020-08-13 → 2025-07-31
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

9 total · 2 active

NIH #R35CA305347

Overcoming Resistance to Targeted Therapy in Breast Cancer

Active
Amount
$1M–$2M
Period
2025-08-20 → 2032-07-31
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA296285

Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.

Active
Amount
$400K–$500K
Period
2025-08-01 → 2030-07-31
PIs
2

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #P50CA247749

Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer

Amount
$400K–$500K
Period
2020-08-13 → 2025-07-31
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA249666

HER2-mediated delivery of cytotoxic agents in solid tumors

Amount
$500K–$600K
Period
2021-04-01 → 2025-03-31
PIs
2

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA245069

Defining the impact of mutant oncogene zygosity

Amount
$400K–$500K
Period
2020-03-01 → 2025-02-28
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA234361

Defining mechanisms of resistance to hormonal therapy in breast cancer

Amount
$400K–$500K
Period
2018-12-05 → 2023-11-30
PIs
2

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA204999

Therapeutic approaches to ER mutant breast cancer

Amount
$400K–$500K
Period
2017-01-01 → 2022-12-31
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA244812

Implications and Vulnerabilities of APOBEC Mutagenesis in Breast Cancer

Amount
$700K–$800K
Period
2020-02-15 → 2020-08-13
PIs
3

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #K08CA134833

Biologic and therapeutic implications of Akt activation in Her2+ breast cancer

Amount
$100K–$200K
Period
2009-09-21 → 2014-08-31
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

Recent Public Signals

  1. New preprint: Microfluidic Tissue Array Platform for Personalized Drug Screening Using Tumor Explants or Biopsies2026-07-02
  2. New paper: Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer (npj Breast Cancer)2026-06-17
  3. New NIH award: Overcoming Resistance to Targeted Therapy in Breast Cancer2025-08-20

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-09-03

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0003-4532-8053

Professor Insights

Career Trajectory